NURSING CARE PLAN

DRUG STUDY

Submitted by:

Mas, Jullianne Danielle A.

Submitted to:

Ms. Joana Marie Junio

Date:

May 18, 2023

 Assessment Nursing Rationale Planning Nursing Intervention Rationale Evaluation/
Diagnosis Possible Outcome

Subjective Cue: Problem Short Term Goal: Independent: Short Term Eval:
Etiology
Objective Cues: Signs & Dependent:
Symptom Long Term Long Term Eval:
Goall: Interdependent/
Collaborative:

1. RANITIDINE
Medication Date Classificatio Indication Mechanism Contraindic Side effect Patient’s Nursing
Ordered/ n of Action ation /Adverse effect Response Responsibilities
Given or
Taken/
Discontinued
Generic: Date Ordered: Classified as a Treatment and Ranitidine is a  Stomach  Stomach After taking Prior:
histamine H2- prevention of competitive cancer. pain this
Ranitidine May 16, 2023 receptor ulcers of the inhibitor of  Porphyria medication, Verify the patient's
antagonist, stomach and histamine H2- .  Constipation the patient history for kidney,
Date Given: and belongs to intestines and receptors. The  Liver shows liver,
Brand: the same drug treatment of reversible problems.  Diarrhea symptoms phenylketonuria, or
May 16,2023 class as gastroesophageal inhibition of  Decreased of nausea porphyria
cimetidine reflux disease. H2-receptors kidney and conditions. Zantac
and in gastric  Headache vomiting. may cause a severe
Zantac Date function.
Discontinued: famotidine. parietal cells bout of porphyria.
results in a  Drowsiness
reduction in During:
Route of  Fatigue
both gastric
Administrati
acid volume Be alert for early
on/ Dosage/
and  Dizziness signs of
Frequency
concentration. hepatotoxicity
Intravenously  Insomnia
After:
/ 50mg/Q⁸
 Nausea
Examine the
patient's feelings
 Vomiting and keep an eye out
for any adverse
reactions.
 2. CEFUROXIME

Medication Date Classificatio Indication Mechanism Contraindic Side effect Patient’s Nursing
Ordered/ n of Action ation /Adverse effect Response Responsibilities
Given or
Taken/
Discontinued
Generic: Date Ordered: Cephalosporin Treatment of Acts by Contraindicated  Blisters The patient Prior:
Antibiotics acute bacterial inhibition of in patients with looks weak
Ceftin May 16, 2023 otitis media, bacterial cell cephalosporin  Tarry and Culture infection, and
several upper wall synthesis. hypersensitivity stools. frequently arrange for sensitivity
Date Given: respiratory or cephamycin feel tests before administer
Brand: tract hypersensitivity  Decrease discomfort
May 16,2023 infections, urine and nausea. During:
skin output
Zinacef Date infections, Monitor allergic
Discontinued: urinary tract reactions and
infections,  Feeling of anaphylaxis
gonorrhea, discomfort.
Route of
early Lyme After:
Administrati  Fever
disease, and
on/ Dosage/
impetigo Notify physician or
Frequency
 Tiredness nursing staff
or immediately if these
Intravenously
weakness. reactions occur.
/ 1.5 g/ Now

3. PARACETAMOL
Medication Date Classificatio Indication Mechanism Contraindic Side effect Patient’s Nursing
Ordered/ n of Action ation /Adverse effect Response Responsibilities
Given or
Taken/
Discontinued
Generic: Date Ordered: Analgesic and Used to Activation of Contraindicated  Hoarseness Nausea and Prior:
antipyretic relieve mild descending in known Vomiting
Acetaminophen May 16, 2023 drugs. or moderate serotonergic hypersensitivity  Difficulty Assess for an allergy to
pain, such as pathways to paracetamol, breathing acetaminophen
Date Given: headaches, in hepatic and or
Brand: toothache or renal failure swallowing During:
May 16,2023 sprains, and
reduce fevers  Red, Observe for
Tylenol Date caused by peeling or Acetaminophen toxicity
Discontinued: illnesses such blistering
as colds and skin. After:
flu.
Route of
Routinely monitor the
Administrati  Rash.
effectiveness of
on/ Dosage/
acetaminophen by
Frequency  Hives. assessing pain levels
and fever reduction
 Itching
Intravenously/
30mg/ Stat

4. UTROGESTAN
Medication Date Classificatio Indication Mechanism Contraindic Side effect Patient’s Nursing
Ordered/ n of Action ation /Adverse effect Response Responsibilities
Given or
Taken/
Discontinued
Generic: Date Ordered: Belongs to the Used to It acts on the Contraindicated  Drowsines Patient Prior:
class of support endometrium when having s and/or appears
Micronized May 16, 2023 pregnen (4) pregnancy by converting abnormal transient sleepy. Utrogestan must not be
derivative during in vitro the vaginal dizziness prescribed until a
Progesterone Date Given: progestogens. fertilization proliferating bleeding which definite cause has been
(IVF) cycles, phase to the is not being established, preferably
May 16,2023 or to prevent a secretory treated, if you via endometrial
Brand: preterm phase. recently had a investigation.
Date singleton birth heart attack or
Discontinued: in certain. stroke and have During:
Utrogestan a blood clotting
disorder. Maintain sterility when
performing the
procedure.
Route of
Administrati
After:
on/ Dosage/
Frequency
Monitor laboratory test
Intravaginally/ results to determine
200mg/ BID possible need for a
reduction in dose and
evaluate for toxicity.

5. MG TNA
Medication Date Classificatio Indication Mechanism Contraindic Side effect Patient’s Nursing
Ordered/ n of Action ation /Adverse effect Response Responsibilities
Given or
Taken/
Discontinued
Generic: Total Date Ordered: Nutrition class Indicated when TPN delivers Irreversibly  Pneumothorax The patient Prior:
of drugs. there is impaired a mixture of decerebrate response in
Parenteral May 16, 2023 gastrointestinal fluid, patients  Air embolism TPN is Obtain complete
function and electrolytes, and with normal. history including
Nutrition Date Given: contraindications sugars, amino critical allergies, drug history.
 Bleeding
to enteral acids cardiovascular
Electrolytes May 16,2023 nutrition. (protein), instability or During:
vitamins, metabolic  Venous
minerals, and instabilities thrombosis Maintain accurate
Date
Brand: Discontinued: often lipids infusion rate and with
(fats) into an  Vascular infusion pump.
patients vein. injury
Nutrilyte, After:

Nutrilyte II Monitor blood

glucose level and
observe for signs of
Route of hyperglycemia and
Administrati hypoglycemia
on/ Dosage/
Frequency
.

Intravenously
/